NewsBenzingaReported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care Benzinga 2026.10.12 07:04 (GMT+0) Open on Benzinga Other news BofA: US memory stock valuations show signs of cycle bottom, market concerns overblown BCX: Invest In Essential Resources, Collect 7% Monthly Income (NYSE:BCX) Tech stocks stumbled. Now comes a crucial week for Wall Street. UnitedHealth: My Thesis Has Played Out, I Wouldn't Chase Here (NYSE:UNH) OFG Bancorp: Risks Remain, But Not Enough To Prevent An Upgrade (NYSE:OFG) Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)
